Professor of Medicine, Harvard Medical School
Chief, Division of Women's Cancers
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Although significant advances have been made in the treatment of metastatic breast cancer, nearly all women with stage IV breast cancer will die of their disease. Drs. Lin and Winer are actively pursuing new and promising alternatives for advanced breast cancer. Over the past several years, with support from BCRF they have completed multiple clinical trials to test new treatments for advanced breast cancer, including trials for patients with cancer that has metastasized (spread) to the brain. Drs. Lin and Winer have also developed several new laboratory models for breast cancer brain metastases, which they are using to test new drug combinations to identify the most promising combinations for future clinical use. They have completed the first part of a trial testing the HER2-directed drug neratinib in patients with brain metastases, and are continuing to test the drug in combination with chemotherapy, as well as evaluating the activity of several novel agents in the brain. Dr. Lin has also co-led an international multidisciplinary effort to improve the design of clinical trials in patients with brain metastases across different types of solid tumors. In addition, the investigators have expanded their efforts more broadly through the EMBRACE (Ending Metastatic Breast Cancer for Everyone) study, which collects blood, tumor tissue, and clinical data and will speed collaborations between the laboratory and clinic. EMBRACE has now enrolled over 800 women and men with advanced breast cancer, with the goal of learning from the experience of each patient in order to provide education and support specific to the needs of patients with metastatic breast cancer. Overall, the team’s work represents the largest broad-based effort to evaluate new systemic options in patients with brain metastases from breast cancer.
Eric P. Winer, MD, is Professor of Medicine at Harvard Medical School and Chief, Division of Women's Cancers and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute. He is also Co-Chair of the Breast Committee of the Alliance for Clinical Trials. Dr. Winer has devoted his professional career to the treatment of individuals with breast cancer and breast cancer research. He has designed and led phase I, II, and III clinical trials. Dr. Winer has collaborated closely throughout his career with psychosocial, health services, basic, and translational researchers. He is the Principal Investigator of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer.
Dr. Winer is a graduate of Yale College, with a degree in History and Russian/East European Studies. He subsequently obtained his medical degree from Yale School of Medicine, followed by training in internal medicine at Yale. He completed a fellowship in medical oncology at Duke University Medical Center and remained on the Duke Faculty until 1997, when we moved to Dana-Farber Cancer Institute in Boston to assume the role of Director of the Breast Oncology Center.